Vinorelbine InjectionUSP 10 & 50 mg is indicated in combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).It is also used as a single agent, for the treatment of patients with metastatic NSCLC.
There are many generic manufacturers in India who manufacture Vinorelbine InjectionUSP 10 & 50 mg including fresenius-kabi etc.
3s corporation is Supplier,Exporter ,Wholesaler for Vinorelbine InjectionUSP 10 & 50 mg in India.
Drug-induced liver injury manifest by elevations of aspartate aminotransferase and bilirubin can occur in patients receiving Vinorelbine alone or in combination with cytotoxic agents.
Severe Constipation and Bowel Obstruction
Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur with Vinorelbine administration.
Extravasation and Tissue Injury
Extravasation of Vinorelbine can result in severe irritation, local tissue necrosis and/or thrombophlebitis.
Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving Vinorelbine.
Pulmonary Toxicity and Respiratory Failure
Pulmonary toxicity, including severe acute bronchospasm, interstitial pneumonitis, acute respiratory distress syndrome (ARDS) occurs with use of Vinorelbine. Interstitial pneumonitis and ARDS included fatalities. The mean time to onset of interstitial pneumonitis and ARDS after Vinorelbine administration was one week (range 3 to 8 days) .
Vinorelbine can cause fetal harm when administered to a pregnant woman. In animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of Vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus.